Notes on Liquid Formulation: Solubility, pH, Co-solvents, Surfactants, Complexation, and Nanoparticles

Overview and Lecture Plan

• Speaker: Kim Chen, professor in pharmaceutics (advanced drug delivery).
• Series: seven lectures in total this term — three on liquid formulation, three on aerosols, and a later one on protein formulation.
• Schedule flexibility: lecture length may be around two hours or up to three; some slides refined just before lecture for clarity.
• Contact: email for questions about lectures; administrative questions handled by Pecker.
• Core objective for today: focus on how to make a drug soluble in aqueous (water) solutions, with occasional use of co-solvents.
• Important caveat: references and AI usage should be checked for accuracy; rely on provided references (e.g., Martin’s Physical Pharmacy) and verify with sources.

Core Principles and Goals of Liquid Formulation

• Main goal in today’s lecture: make the drug soluble in a water-based solution.
• Co-solvent concept: when water alone cannot dissolve enough drug, add a co-solvent (typically alcohol like ethanol; other examples include glycerol, propylene glycol).
• Most liquid formulations are aqueous (water-based) and contain the drug plus excipients; sometimes organic solvents are used.
• The three top considerations when formulating any dosage form (including liquids): deliverable, bioavailable, and stable.
• For liquids, focus is on delivering drug in water or water-based solutions; stability in solution can be more challenging than in solid form due to increased molecular mobility.

Types of Liquid Formulations and Key Definitions

• Liquid formulations include:
  • Oral liquids (solutions, with or without sweeteners and flavoring);
  • Injectables in solution (intramuscular, IV, subcutaneous);
  • Nebulized solutions;
  • Eye drops; and others (suspensions are discussed as a separate, less ideal liquid-type since they are two-phase).
• Definition nuance: a true liquid formulation for this course is a homogeneous, single-phase solution where the drug and additives are dissolved in the aqueous medium.
• Suspensions contain solid particles in liquid and may require shaking before use to re-disperse; liquids for this course aim to be homogeneous and readily dose-without settling.

Advantages and Limitations of Liquid Formulations (Pros and Cons)

• Advantages:
  • Bypasses disintegration and dissolution steps required for tablets; typically faster onset.
  • Easier swallowing for patients who have difficulty with tablets (pediatric and some geriatric patients).
  • More uniform dosing since the formulation is homogeneous.
• Limitations and challenges:
  • Stability concerns: liquids generally have shorter shelf-life than solids due to chemical degradation and increased molecular mobility.
  • Solubility: not all drugs dissolve in water; solubility issues are a central challenge in liquid formulation.
  • Taste and palatability: need flavoring and sweetening agents for oral formulations; sometimes this affects stability and regulatory acceptance.
• Visual contrast: liquids are homogeneous (no phase separation); suspensions and emulsions are two-phase systems and require agitation before use.

Key Concepts: Deliverable, Bioavailable, Stable

• When formulating a liquid dosage form, always consider:
  • Deliverable: can you deliver the required dose with the chosen solvent system without requiring impractically large volumes?
  • Bioavailable: after administration, is the drug available at the site of action? Examples show that route of administration strongly affects bioavailability (e.g., inhaled vs injected vs oral).
  • Stable: the drug must remain chemically and physically stable for the intended shelf life; proteins and some small molecules may degrade quickly in solution.
• Examples discussed:
  • Protein formulations have particular stability concerns in solution.
  • For inhaled therapies (aerosols), delivery to the site of action (e.g., lungs) can improve bioavailability for certain drugs.
• In addition to formulation, device and route of administration (e.g., inhalers, injection pens) influence delivery, bioavailability, and stability.

The “Dissolves the Like” Concept (Polarity and Solubility Basics)

• Core idea: polar (hydrophilic) substances dissolve well in water; non-polar (hydrophobic) substances tend to dissolve in organic solvents (e.g., alcohol).
• Visual metaphor used: water (polar) vs ethanol (contains nonpolar C–H groups) interacts with drug polarity.
• Practical takeaway: if a drug is hydrophobic and not ionizable, co-solvents like alcohol might help solubilize the unionized form; ionization changes solubility in water (through pH) but may be hampered by the co-solvent’s dielectric effects.
• Key concept link: ionization state depends on pH and the drug’s acid/base character (Ka/Kb). The presence of co-solvents alters solvent dielectric properties and can suppress or enhance ionization depending on the system.

pH Adjustment and Ionization (Ionizable Drugs)

• Many drugs are weak acids or weak bases; modifying pH can shift the equilibrium between unionized (non-ionized) and ionized forms, altering solubility.
• For a weak acid (HA):
  • Dissociation: $K_a = \frac{[H^+][A^-]}{[HA]}$
  • In water, total solubility ST is the sum of unionized and ionized species: $S</em>T = [HA] + [A^-]$
  • Relationship: [A^-] = rac{K_a[HA]}{[H^+]}
  • Therefore: ST = [HA]iggl(1 + rac{Ka}{[H^+]}iggr)
  • If the unionized concentration at saturation is DH (i.e., [HA] = DH), then the total solubility becomes: ST = DHiggl(1 + rac{K_a}{[H^+]}iggr)
  • Solve for [H+]: [H^+] = rac{Ka}{rac{ST}{DH} - 1}$and then$ ext{pH} = -rac{}{} ext{log}{10}([H^+])
• For a weak base (B):
  • Dissociation: Kb = rac{[BH^+][OH^-]}{[B]}$with$[OH^-] = rac{Kw}{[H^+]}
  • Ionized fraction: rac{[BH^+]}{[B]} = rac{Kb[H^+]}{Kw}
  • Total solubility: ST = [B] + [BH^+] = [B]iggl(1 + rac{Kb[H^+]}{K_w}iggr)
  • If the unionized concentration at saturation is DHB (i.e., [B] = DHB), then: ST = D{HB}iggl(1 + rac{Kb[H^+]}{Kw}iggr)
  • Solve for [H+]: [H^+] = rac{Kw}{Kb}iggl(rac{ST}{D{H_B}} - 1iggr)^{-1} and then compute pH as above.
• Henderson–Hasselbalch form (for buffers) is used to relate pH, pKa, and the ratio of conjugate base to acid:
  • For acid: ext{pH} = ext{p}K_a + ext{log}iggl(rac{[A^-]}{[HA]}iggr)
  • For base: analogous form using the conjugate acid and base.
• Practical notes:
  • Maximum buffer capacity occurs when [HA] ≈ [A^-], i.e., pH ≈ pKa.
  • In strong buffering, volume and ionic strength can influence solubility and stability; calculations are followed by pH verification with a pH meter.

Buffer Preparation and Buffer Capacity

• Do you always need a buffer?
  • Not always; depends on drug stability across pH. If the drug is highly stable across the intended pH window, a buffer may be unnecessary.
  • If the drug is pH-sensitive, a buffer helps maintain solubility and stability when open to air (CO2 uptake can change pH).
• Buffer criteria:
  • Non-toxic and chemically compatible with the drug and other excipients.
  • Adequate buffering capacity for the expected pH drift and storage conditions.
  • pH set to roughly the desired value using Henderson–Hasselbalch and then confirmed via pH measurement.
• Buffer capacity concept: maximum when acid and conjugate base are in equal concentrations, so that the buffer can neutralize added acid or base most effectively around pH = pKa.
• Practical note: choose buffer species with a suitable pKa near the target pH and compatible with the drug and dosage form.

Co-Solvent Strategy: Using Alcohols and Other Miscible Solvents

• Co-solvent definition: use of an organic solvent (often ethanol) that is miscible with water to increase overall drug solubility, especially for unionized forms.
• Key ideas:
  • Co-solvents can increase the total solubility S_T by increasing the solubility of the unionized form, not solely by ionization.
  • Dielectric constant effect: organic solvents lower the effective dielectric constant of the solvent mixture, which can suppress ionization for ionizable drugs—a balance must be found.
  • For ionizable drugs, pH adjustment and co-solvents interact: co-solvents may reduce ionization (lower dielectric constant), decreasing ionized solubility, while potentially increasing unionized solubility; the net effect depends on the drug and its pKa.
• Dielectric constant concept:
  • Dielectric constant (ε) measures energy required to separate charges in a solvent; higher ε stabilizes ions more effectively.
  • Water: ε ≈ 80; Ethanol: ε ≈ 24; Glycerol: ε ≈ 42 (approximate values from lecture).
  • Presence of a co-solvent reduces the effective dielectric constant, which can reduce drug ionization and alter solubility balance.
• Key takeaway: always consider whether the drug species in solution are ionized or unionized; with co-solvents, total solubility is a balance between ionized and unionized solubility.
• Example discussions:
  • Amoxicazole and paracetamol elixirs often use ethanol or propylene glycol as co-solvents to improve solubility.
  • In phenobarbital (a weak acid, pK_a ≈ 7.3), curves show how solubility in ethanol-water mixtures changes with pH (curves at pH 2–6, 8–9, 10) before and after adding alcohol.
  • Phenobarbital example demonstrates that near pH values where ionization is high, adding alcohol can reduce ionization (due to dielectric effect) and may decrease solubility unless the unionized solubility increase compensates.
• Practical guidelines:
  • Select a co-solvent that is miscible with water, has acceptable toxicity, and is acceptable for the route of administration.
  • Keep co-solvent amounts to acceptable levels (often a few percent up to 10% in pediatric formulations, depending on regulatory guidelines).
  • Evaluate solubility, stability, and irritation potential for the specific drug and route.
• Example co-solvents mentioned: ethanol, glycerol, propylene glycol; common practice is to use ethanol/propylene glycol mixtures for many oral liquid formulations.

Case Studies: Solubility in Co-Solvent Systems

• Phenobarbital (weak acid, pK_a ≈ 7.3) solubility in water and in ethanol-containing mixtures:
  • As pH increases (more alkaline), ionization increases, solubility generally increases because more A^- is present.
  • When ethanol is added, the dielectric constant drops, which can suppress ionization and reduce ionized solubility; however, unionized solubility can increase, leading to a complex balance.
  • At very high pH (e.g., pH 10), the majority of drug is ionized; adding ethanol can reduce ionization but may increase unionized solubility; the net effect depends on the magnitudes and balance of ionized vs unionized forms.
• Overall lesson: co-solvents can increase total solubility by enhancing unionized solubility, but their presence can suppress ionization; expect non-monotonic changes in S_T with increasing co-solvent content and changing pH.

Micellar Solubilization (Surfactants and Micelles)

• Concept: surfactants self-assemble into micelles above the critical micelle concentration (CMC). Micelles have a hydrophobic core and a hydrophilic exterior.
• Mechanism: hydrophobic drugs partition into the micellar core, increasing apparent solubility in water.
• Surfactant properties:
  • Usually ionic or nonionic; common hydrophilic-lipophilic balance (HLB) values guide solubilization ability; values typically > 15 indicate good solubilizing capacity.
  • Common surfactants: polysorbate (Tween) series, cetomacrogol (cetyl/PEG ethers), cetyltrimethylammonium bromide (CTAB) etc. In practice, polysorbate 80 (Tween 80) is widely used; shorthand “Tween 80” is common in the industry.
• Practical considerations:
  • Use the minimum amount of surfactant to achieve a clear solution (avoid foaming and toxicity).
  • Surfactants can foaming and potential toxicity; choose concentrations at or just above CMC to form micelles without excessive foaming.
• Examples illustrating micellar use:
  • Fat-soluble vitamins ADEK solubilized with Tween 80 and cetomacrogol.
  • Griseofulvin (antifungal) solubilized using micellar systems.
  • Cyclosporine for dry eye formulated with micelles to achieve higher local concentrations.
• Daily-life example: inclusion of surfactants in various products to enhance solubility and palatability.
• Important note: micellar solubilization is primarily a physical approach to increase solubility; it does not chemically alter the drug but increases its apparent solubility in the liquid matrix.

Complexation and Cyclodextrins

• Complexation concept: a drug (D) can form a complex with a complexing agent (C) to form DC. General equilibrium: D + C ⇌ DC with stability constant KS = [DC]/([D][C]).
• Total drug solubility: ST = [D] + [DC]. When C is added, ST increases until the complexation capacity is saturated.
• One-to-one complexation (typical): if one molecule of drug complexes with one molecule of complexing agent, then the simple relation applies: S_T = [D] + [DC].
• Key points:
  • The complexation must be reversible so that the drug can dissociate in vivo to bind the receptor and achieve bioavailability.
  • Excess complexing agent can pull drug into solution up to a limit; beyond that, excess drug can precipitate out or remain undissolved.
• Cyclodextrins (CDs) as a special class of complexing agents:
  • Cyclodextrins are cyclic oligosaccharides with hydrophobic inner cavities and hydrophilic outer surfaces.
  • Types and sizes:
  • Alpha-cyclodextrin: 6 glucose units; interior diameter ~0.6 nm.
  • Beta-cyclodextrin: 7 units; interior diameter ~0.7 nm.
  • Gamma-cyclodextrin: 8 units; interior diameter ~0.9 nm.
  • Inclusion exchange: drugs that fit well into the aromatic/hydrophobic cavity can form 1:1 complexes with CDs, improving aqueous solubility and sometimes stabilizing the drug from light/oxygen exposure.
  • Size and fit matter: if the molecule is too large, it may not fit into the cavity (alpha often too small for many drugs).
• Practical examples and notes:
  • Inclusion complexes can improve solubility and sometimes stability and taste (masking bitterness).
  • Cyclodextrins are particularly useful for hydrophobic drugs and for masking taste or protecting photosensitive compounds.
  • Cyclodextrins must be used with consideration of toxicity and regulatory guidelines; some CDs are not suitable for certain routes of administration.
• Betadine example (complexing with polymer PVP):
  • Povidone (PVP) forms a complex with iodine to enable solubility and controlled release; this is an example of a complexing agent in practice, distinct from cyclodextrin inclusion.
• Fiovaline example (complex with salicylate):
  • A drug that forms a one-to-one complex with salicylate; complexation aids solubility while maintaining bioactivity.
• Bottom line: complexation provides a route to solubility enhancement by leveraging reversible binding to a second molecule forming a soluble complex.

Chemical Modification to Increase Solubility

• Concept: chemically alter the drug to introduce ionizable or hydrophilic groups or to form salts, increasing aqueous solubility without altering receptor binding substantially.
• Examples:
  • Prednisolone phosphate (phosphate ester) forms a sodium salt increasing water solubility; the phosphate group introduces a hydrophilic, ionizable moiety while preserving pharmacophore compatibility.
  • Chloramphenicol succinate: attachment of a succinate (a carboxyl-containing group) forms a sodium salt increasing aqueous solubility.
• Critical caveat: modifications must not disrupt receptor binding or pharmacodynamics; the added functional group should not hinder the drug’s mechanism of action.
• Practical implication: chemical modification is a powerful strategy when physical solubility is insufficient, and can be tailored to preserve biological activity while enhancing solubility.

Nanoparticles and the Kelvin Equation (Particle Size Reduction)

• Idea: reducing particle size to the nanoscale can increase apparent solubility due to changes in surface energy and dissolution kinetics.
• Kelvin equation (conceptual form): relates solubility Sr of a particle with radius r to the bulk solubility S∞:
  • Qualitative form: ext{ln}iggl(rac{Sr}{S ext{∞}}iggr) = rac{2 \, eta \, V_m}{r \, R \, T}
  • Alternatively: Sr = S ext{∞} \, ext{exp}iggl(rac{2 \gamma V_m}{r R T}\biggr)
  • Here, γ is the interfacial surface tension, V_m is the molar volume, R is the gas constant, T is temperature, and r is particle radius.
• Practical takeaway: as particle radius r decreases (nanoscale), S_r increases, offering higher apparent solubility.
• Reality check: while theoretically attractive, producing and stabilizing nanoparticles (sub-100 nm) can be technically challenging and may introduce stability and safety considerations.

Practical Manufacturing and Regulatory Considerations for Liquid Formulations

• Manufacturing workflow (simplified):
  • Dissolve active ingredient and excipients into water (and co-solvents if used) to form a clear solution.
  • Filter to remove undissolved solids (sterile filtration if needed).
  • Fill into final containers; sterilize if required by route (e.g., eye drops, parenterals).
• Water quality and sterility:
  • Use purified water; monitor microbial content with regulatory limits.
  • Sterilization methods: UV, filtration through 0.22 μm filters; appropriate for the route and formulation.
• Preservatives:
  • May be used for multi-dose containers to prevent microbial growth; not always required; selection is broad-spectrum and compatible with the drug.
• Thickeners and viscosity modifiers:
  • For oral liquids to improve palatability, pourability, or ease of dosing.
  • Common options include various polymers like PVP, cellulose derivatives, etc.
• Density and tonicity:
  • Density matching with vehicle or tissues can be relevant for certain routes (e.g., spinal injections) to minimize movement; tonicity adjustments ensure minimal irritation and compatibility with physiological fluids.
• Color and appearance:
  • Colorants may be used for identification or marketing; regulatory requirements require disclosure of degradation products and acceptable levels.
  • In some cases, coloration is used for aesthetic or compliance reasons; however, it must be acceptable and non-malsregulated.
• Specific application examples:
  • Non-aqueous (oily) liquids for external use or specialized routes; not all liquids are aqueous.
  • For ocular/eye drops, isotonicity and sterility are critical; for oral liquids, palatability and stability take precedence.
• Special case examples:
  • Insulin injection pens require certain excipients and preservatives due to multi-dose use;
  • Patch or topical formulations often include thickening agents and complex solubility aids to improve skin contact and absorption.
• A note on safety and ethics:
  • Degradation products must be disclosed and within acceptable regulatory limits.
  • Sucrose-containing formulations can hydrolyze outside pH 4–8; pH constraints and stability must be considered.
  • Avoid hiding degradation products with color changes or misleading appearance; regulatory approvals require transparency.

Real-World Examples and Practical Takeaways

• Serial use of excipients in everyday products can illustrate these concepts:
  • ADEK vitamins: fat-soluble vitamins solubilized using micelles or surfactants.
  • Griseofulvin: commonly solubilized with surfactants in micellar systems.
  • Cyclosporine (for dry eye): micellar formulations to improve ocular bioavailability.
  • Betadine (povidone-iodine): iodine complexed with polyvinylpyrrolidone (PVP) to improve solubility and handling; this is a practical example of a complexing agent.
  • Fiovaline complexation with salicylate: another example of complexation enhancing solubility.
  • Cyclodextrin-based inclusion: used to solubilize hydrophobic drugs via inclusion complexes; alpha (6 units) often too small for larger molecules; beta (7 units) commonly used; gamma (8 units) usable for somewhat larger molecules; interior diameters roughly 0.6–0.9 nm.
• Capsule and tablet interactions with liquids:
  • Liquids can be easier to dose, but ensure palatability, stability, and regulatory compliance; always consider whether preservatives are necessary for multi-dose containers.
• Final notes on practice and ethics:
  • The lecturer emphasizes critical thinking about how to enhance solubility using physical, chemical, and formulation strategies rather than relying solely on technology.
  • Students should be prepared to justify the choice of method (pH adjustment, co-solvent, micellar, cyclodextrin, chemical modification, or nanoparticle) based on drug properties (Ka, Kb, pKa, logP, MW), stability, route, and safety considerations.

Summary of Key Formulation Tools (At a Glance)

• pH adjustment (ionization control) for acid/base drugs with Henderson–Hasselbalch framework:
  • Weak acid: K_a = rac{[H^+][A^-]}{[HA]}; solubility balance leads to solving for [H^+].
  • Weak base: Kb = rac{[BH^+][OH^-]}{[B]}$; use relation to [H^+] via$Kw = Ka Kb$$ and Henderson–Hasselbalch form for bases.
• Co-solvent strategy: alcohols and glycols reduce dielectric constant, affecting ionization; add to increase unionized solubility while monitoring ionization losses.
• Micellar solubilization: use minimal surfactant above CMC to form micelles that solubilize hydrophobic drugs; select surfactants with suitable HL values; avoid excessive foaming/toxicity.
• Complexation: employ cyclodextrins (alpha/beta/gamma) or other complexing agents (PVP, salicylate) to form soluble complexes; ensure reversibility and bioavailability.
• Chemical modification: convert drug into salt or ester (phosphate, succinate) to enhance water solubility while maintaining receptor binding.
• Nanoparticles (Kelvin equation): nanoscale particles exhibit higher apparent solubility due to curvature effects; consider practical manufacturing limitations.
• Manufacturing and regulatory constraints: ensure solubility, stability, sterility, isotonicity, palatability, and full disclosure of degradation products; verify with regulatory guidance (APF references and similar sources).

Final Thoughts and Practical Implications

• The lecture emphasizes that liquid formulation is not just about dissolving a drug in water; it requires a careful balance of solubility, stability, taste, dosing accuracy, and regulatory compliance.
• A good formulation often combines several strategies (e.g., pH adjustment + co-solvent + micellar solubilization) to achieve the desired solubility and stability without compromising safety or efficacy.
• Students should be prepared to justify the choice of solubility enhancement technique based on specific drug properties (ionization state, solubility, logP, MW, stability) and intended route of administration.
• Finally, consider the real-world constraints: manufacturability, patient acceptability, regulatory requirements, and the potential for future AI-assisted formulation design while validating with reliable references.

Next Lecture Preview

• Upcoming lectures will cover aerosols (inhalation formulations), followed by protein formulation topics.
• Expect a mix of theory, practical examples, and problem-solving sessions similar to today’s exercise with real data and calculations.